|
Northwest Biotherapeutics wants to bring out the killer in you. The development-stage firm's DCVax vaccine platform uses dendritic cells (a type of white blood cells) obtained from a patient's blood to program that patient's own T cells to kill cancer cells. Northwest Biotherapeutics' two DCVax product candidates are being targeted to treat brain and prostate cancer. Both candidates are in late stage clinical trials. If successful, the therapies could work in conjunction with more traditional cancer treatments. Toucan Capital holds over 85% of the company's shares. Toucan's Cognate Therapeutics subsidiary manufactures the DCVax products and provides additional services to Northwest Biotherapeutics.
|
| | | Contact Information | |
Address: |
7600 Wisconsin Ave., Ste. 750
Bethesda, MD 20814
| | Phone: | 240-497-9024 | | Fax: | |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 0.00 M | | Revenue Growth (1 yr): | 0.00% | | Employees (2008): | 4 | | Employee Growth (1 yr): | (-42.90%) |
|
|
Key People
| | • |
Chairperson:
Linda F. Powers
| | • |
President, CEO, Secretary, and Director:
Alton L. Boynton
| | • |
CTO:
Marnix L. Bosch
|
|
|
